Kevin Walsh

Kevin Walsh, an associate in Goodwin’s Antitrust and Competition practice, focuses his practice on advising domestic and multinational businesses and private equity firms on their obligations under the Hart-Scott-Rodino Antitrust Improvements Act and foreign merger control regimes, assessing reportability and antitrust risk for a wide variety of complex transactions involving mergers and acquisitions, license agreements, and venture capital financing.

Kevin’s recent representative experience includes:

• Mariana Oncology in its acquisition by Novartis for $1 billion upfront, and up to $750 million in milestones
• Shanghai Argo Biopharmaceutical Co., Ltd. In its two exclusive license and collaboration agreements with Novartis
• Miro in its acquisition of the visual collaboration platform, Freehand, from InVision
• Thoma Bravo in its acquisition of NextGen Healthcare, Inc. for $1.8 billion
• EQRx, Inc. in its acquisition by Revolution Medicines
• Talon Cyber Security in its acquisition by Palo Alto Network
• Manta Software in its acquisition by IBM
• Advanced Biologics in its merger with Isto Biologics
• KBP Biosciences in its sale of ocedurenone to Novo Nordisk for up to $1.3 billion
• Acino in its acquisition of M8 Pharmaceuticals
• Orionis Biosciences on its multi-year collaboration agreement with Genetech
• TA Associates and Warburg Pincus on their agreement to jointly acquire majority stake in Epassi Group from majority shareholder Bregal Milestone
• Nanobiotix S.A. in its licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV
• Bobbie in its acquisition of Nature’s One
• Summit Partners in its sale of shares in Elatec group to SGT German Private Equity
• Honest Day’s Work in its acquisition by Latch, Inc.
• Moderna on its $76 million strategic collaboration with Generation Bio Co. to develop non-viral genetic medicines
• OncoC4 in its strategic collaboration with BioNTech to co-develop and commercialize novel checkpoint antibody in multiple solid tumor indication
• Sichuan Kelun-Biotech Biopharmaceutical in its exclusive license and collaboration ADC agreement with Merck for $9.5 billion
• Biocon Biologics in its acquisition of Viatris for approximately $3.3 billion
• Pixomondo in its acquisition by Sony Pictures Entertainment
• Ritchie Bros. in its acquisition of IAA, Inc. for $7.3 billion
• TA Associates in its significant strategic growth investment in Veracode
• Abingworth on its acquisition by Carlyle
• Backstage Holdings in its acquisition by Cast & Crew
• Novo in its $90 million Series B financing
• SWORD Health in its $163 million Series D financing

Kevin is a member of the Boston and American Bar Associations.

Kevin has been recognized by The Best Lawyers in America for his work in Antitrust Law and Litigation – Antitrust since 2024.

Kevin is a contributor to Goodwin’s Antitrust Trends in Technology, Life Sciences, and Healthcare series, which provides quarterly analysis and commentary on antitrust developments. Kevin also regularly provides updates on the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the HSR Act).